{
    "clinical_study": {
        "@rank": "109394", 
        "acronym": "AN-PEP-03", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 Placebo pills"
            }, 
            {
                "arm_group_label": "AN-PEP 80.000 PPI", 
                "arm_group_type": "Experimental", 
                "description": "1 pill AN-PEP 80.000 PPI and 1 pill Placebo."
            }, 
            {
                "arm_group_label": "AN-PEP 160.000 PPI", 
                "arm_group_type": "Experimental", 
                "description": "2 pills AN-PEP 80.000 PPI"
            }
        ], 
        "brief_summary": {
            "textblock": "In this trial, the effect of a low and a high dose AN-PEP will be investigated in gluten\n      sensitive individuals. Volunteers receive a breakfast with background (0.5 g) gluten.\n      Capsules are taken in the morning within 5 min after start of breakfast. Gastrointestinal\n      fluid will be sampled over 3 hours to measure gluten degradation. After 5 volunteers have\n      completed 3 test days, a blind interim analysis is performed by a third party based on which\n      it is decided whether to proceed with the low AN-PEP dose."
        }, 
        "brief_title": "Effect of AN-PEP Enzyme on Gluten Digestion in Gluten Sensitive Individuals", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-coeliac Gluten Sensitivity", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male/female\n\n          -  Age \u226518 but <70 yr\n\n          -  Females: Hormonal contraceptive treatment\n\n          -  Self-reported gluten-sensitive individuals fulfilling the Rome III criteria while\n             consuming gluten\n\n          -  Subject has read and understood the information provided on the study and given\n             written informed consent\n\n        Exclusion Criteria:\n\n          -  Coeliac disease serology while consuming gluten (serological test for tissue\n             transglutaminase IgA antibodies and total IgA antibodies)\n\n          -  Wheat allergy (serological test for wheat protein IgE antibodies)\n\n          -  Medication or medical condition that affects gastric emptying or secretion\n\n          -  Females: Pregnancy or breast-feeding\n\n          -  Inability to swallow the gastroduodenal feeding tube\n\n          -  Any medical condition that in the opinion of the investigators may interfere with the\n             study and may jeopardise the health status of the participant\n\n          -  Any condition that in the opinion of the investigators may interfere with the study\n             and may jeopardise the health status of the participant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060864", 
            "org_study_id": "AN-PEP-03"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AN-PEP 80.000 PPI", 
                    "AN-PEP 160.000 PPI"
                ], 
                "description": "Two pills are consumed in the morning with a breakfast", 
                "intervention_name": "AN-PEP", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Aspergillus Niger-Prolyl Endopeptidase"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "enzyme", 
            "gluten", 
            "food intolerance"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "\u00d6rebro", 
                    "country": "Sweden", 
                    "zip": "701 82"
                }, 
                "name": "\u00d6rebro University"
            }, 
            "investigator": [
                {
                    "last_name": "Robert Jan Brummer, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Julia K\u00f6nig, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of the Enzyme AN-PEP on Gluten Degradation in the Stomach of Gluten-sensitive Individuals", 
        "overall_contact": {
            "email": "Julia.Konig@oru.se", 
            "last_name": "Julia K\u00f6nig, PhD", 
            "phone": "+46 19 30 36 45"
        }, 
        "overall_contact_backup": {
            "email": "Robert.brummer@oru.se", 
            "last_name": "Robert Brummer, MD PhD", 
            "phone": "+46 19 30 37 31"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Effect of AN-PEP (160.000 PPI) on gluten degradation based on amount of gluten detected in the duodenum compared with placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)", 
            "measure": "Effect of 160.000 PPI AN-PEP on duodenal gluten", 
            "safety_issue": "No", 
            "time_frame": "3-hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060864"
        }, 
        "responsible_party": {
            "investigator_affiliation": "\u00d6rebro University, Sweden", 
            "investigator_full_name": "Robert Brummer", 
            "investigator_title": "Prof", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Effect of AN-PEP (160.000 PPI) on gluten degradation based on amount of gluten detected in the stomach compared with placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)", 
                "measure": "Effect of 160.000 PPI AN-PEP on gastric gluten", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }, 
            {
                "description": "Effect of AN-PEP (80.000 PPI) on gluten degradation based on amount of gluten detected in the duodenum compared to placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)", 
                "measure": "Effect of 80.000 PPI AN-PEP on duodenal gluten", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }, 
            {
                "description": "Effect of AN-PEP (80.000 PPI) on gluten degradation based on amount of gluten detected in the stomach compared to placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)", 
                "measure": "Effect of 80.000 PPI AN-PEP on gastric gluten AUC", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }, 
            {
                "description": "The average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (160.000 PPI) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the duodenum compared with placebo over 180 min using AUC.", 
                "measure": "Effect of 160.000 PPI AN-PEP on percentage duodenal gluten reduction", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }, 
            {
                "description": "The average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (160.000 PPI) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the stomach compared with placebo over 180 min using AUC.", 
                "measure": "Effect of 160.000 PPI AN-PEP on percentage gastric gluten reduction", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }, 
            {
                "description": "The average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (80.000 PPI) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the duodenum compared with placebo over 180 min using AUC.", 
                "measure": "Effect of 80.000 PPI AN-PEP on percentage duodenal gluten reduction", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }, 
            {
                "description": "The average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (low and high dose) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the stomach compared with placebo over 180 min using AUC.", 
                "measure": "Effect of 80.000 PPI AN-PEP on percentage gastric gluten reduction", 
                "safety_issue": "No", 
                "time_frame": "3-hour"
            }
        ], 
        "source": "DSM Food Specialties", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DSM Food Specialties", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}